Dataset Information

Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.

ABSTRACT: The rigorous testing of hypotheses on suitable sample cohorts is a major limitation in translational research. This is particularly the case for the validation of protein biomarkers; the lack of accurate, reproducible, and sensitive assays for most proteins has precluded the systematic assessment of hundreds of potential marker proteins described in the literature. Here, we describe a high-throughput method for the development and refinement of selected reaction monitoring (SRM) assays for human proteins. The method was applied to generate such assays for more than 1000 cancer-associated proteins, which are functionally related to candidate cancer driver mutations. We used the assays to determine the detectability of the target proteins in two clinically relevant samples: plasma and urine. One hundred eighty-two proteins were detected in depleted plasma, spanning five orders of magnitude in abundance and reaching below a concentration of 10 ng/ml. The narrower concentration range of proteins in urine allowed the detection of 408 proteins. Moreover, we demonstrate that these SRM assays allow reproducible quantification by monitoring 34 biomarker candidates across 83 patient plasma samples. Through public access to the entire assay library, researchers will be able to target their cancer-associated proteins of interest in any sample type using the detectability information in plasma and urine as a guide. The generated expandable reference map of SRM assays for cancer-associated proteins will be a valuable resource for accelerating and planning biomarker verification studies.

SUBMITTER: Huttenhain R

PROVIDER: S-EPMC3766734 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.

Hüttenhain Ruth R Soste Martin M Selevsek Nathalie N Röst Hannes H Sethi Atul A Carapito Christine C Farrah Terry T Deutsch Eric W EW Kusebauch Ulrike U Moritz Robert L RL Niméus-Malmström Emma E Rinner Oliver O Aebersold Ruedi R

Science translational medicine 20120701 142

The rigorous testing of hypotheses on suitable sample cohorts is a major limitation in translational research. This is particularly the case for the validation of protein biomarkers; the lack of accurate, reproducible, and sensitive assays for most proteins has precluded the systematic assessment of hundreds of potential marker proteins described in the literature. Here, we describe a high-throughput method for the development and refinement of selected reaction monitoring (SRM) assays for human ...[more]

PMID: 22786679

Similar Datasets

Project description:Accurate biomarkers are a crucial and necessary precondition for precision medicine, yet existing ones are often unspecific and new ones have been very slow to enter the clinic. Mass spectrometry (MS)-based proteomics excels by its untargeted nature, specificity of identification, and quantification, making it an ideal technology for biomarker discovery and routine measurement. It has unique attributes compared to affinity binder technologies, such as OLINK Proximity Extension Assay and SOMAscan. In in a previous review in 2017, we described technological and conceptual limitations that had held back success. We proposed a 'rectangular strategy' to better separate true biomarkers by minimizing cohort-specific effects. Today, this has converged with advances in MS-based proteomics technology, such as increased sample throughput, depth of identification, and quantification. As a result, biomarker discovery studies have become more successful, producing biomarker candidates that withstand independent verification and, in some cases, already outperform state-of-the-art clinical assays. We summarize developments over the last years, including the benefits of large and independent cohorts, which are necessary for clinical acceptance. Shorter gradients, new scan modes, and multiplexing are about to drastically increase throughput, cross-study integration, and quantification, including proxies for absolute levels. We have found that multiprotein panels are inherently more robust than current single analyte tests and better capture the complexity of human phenotypes. Routine MS measurement in the clinic is fast becoming a viable option. The full set of proteins in a body fluid (global proteome) is the most important reference and the best process control. Additionally, it increasingly has all the information that could be obtained from targeted analysis although the latter may be the most straightforward way to enter regular use. Many challenges remain, not least of a regulatory and ethical nature, but the outlook for MS-based clinical applications has never been brighter.

Project description:Spiculations are important predictors of lung cancer malignancy, which are spikes on the surface of the pulmonary nodules. In this study, we proposed an interpretable and parameter-free technique to quantify the spiculation using area distortion metric obtained by the conformal (angle-preserving) spherical parameterization. We exploit the insight that for an angle-preserved spherical mapping of a given nodule, the corresponding negative area distortion precisely characterizes the spiculations on that nodule. We introduced novel spiculation scores based on the area distortion metric and spiculation measures. We also semi-automatically segment lung nodule (for reproducibility) as well as vessel and wall attachment to differentiate the real spiculations from lobulation and attachment. A simple pathological malignancy prediction model is also introduced. We used the publicly-available LIDC-IDRI dataset pathologists (strong-label) and radiologists (weak-label) ratings to train and test radiomics models containing this feature, and then externally validate the models. We achieved AUC = 0.80 and 0.76, respectively, with the models trained on the 811 weakly-labeled LIDC datasets and tested on the 72 strongly-labeled LIDC and 73 LUNGx datasets; the previous best model for LUNGx had AUC = 0.68. The number-of-spiculations feature was found to be highly correlated (Spearman's rank correlation coefficient ρ=0.44) with the radiologists' spiculation score. We developed a reproducible and interpretable, parameter-free technique for quantifying spiculations on nodules. The spiculation quantification measures was then applied to the radiomics framework for pathological malignancy prediction with reproducible semi-automatic segmentation of nodule. Using our interpretable features (size, attachment, spiculation, lobulation), we were able to achieve higher performance than previous models. In the future, we will exhaustively test our model for lung cancer screening in the clinic.

Dataset Information

Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.

Publications

Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets